My research focuses on advancing immunotherapeutic approaches to the treatment of solid tumors, with a particular focus on adoptive cell therapy. I have dedicated clinical expertise in cutaneous oncology and sarcomas, though I treat all solid tumors through clinical research in early phase drug development. I helped to complete and report a practice-changing study of anti-PD-1 plus low-dose ipilimumab after prior anti-PD-1 failure in advanced melanoma. Within my institution, I am leading multiple immunotherapy clinical trials including tumor-infiltrating lymphocyte (TILs), TCR T cell, and CAR-T cell therapies. I also lead studies targeting immune checkpoints and agonists (DGKz, OX40L) and innate immune agonists (STING). I have also contributed to translational research relating to biomarkers of immunotherapy response and immune-related adverse events (irAEs) to checkpoint therapy.